Priority 3 from the Juvenile Idiopathic Arthritis (Netherlands) PSP
| UNCERTAINTY: What is the best treatment plan for uveitis in JIA, and are there factors that predict its effectiveness? (JLA PSP Priority 3) | |
|---|---|
| Overall ranking | 3 |
| JLA question ID | 0094/3 |
| Explanatory note | This question is specifically about uveitis in JIA, which occurs in approximately 20% of the cases of JIA. It causes a significant burden of disease, which is why it is so high in the top 10. Respondents wanted to know what the best treatment plan is for uveitis, and whether this can be predicted (linking to question 2). |
| Evidence |
Systematic review-based + expert panel - Angeles-Han et al. 2019 American College of Rheumatology/Arthritis Foundation guidelinge for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res 2019;71:703. |
| Health Research Classification System category | Inflammatory and immune system |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | See data spreadsheet on JLA website |
| Submitted by | See data spreadsheet on JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0094 |
| PSP name | Juvenile Idiopathic Arthritis (Netherlands) |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 7 February 2020 |